Subsidiary of Guangzhou Baiyunshan Pharmaceutical Holdings (00874) plans to invest approximately 500 million yuan to acquire 100% equity of Zhejiang Provincial Pharmaceutical Industry Co., Ltd.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that on December 17, 2025, the buyer (Guangzhou Pharmaceuticals, a subsidiary of the company) and the seller (Zhejiang Hisun Pharmaceutical, an independent third party company) entered into a stock transaction agreement and supplemental agreement. According to the stock transaction agreement and supplemental agreement, the buyer intends to acquire 100% equity of Zhejiang Pharmaceutical Industry Co., Ltd., with a purchase price of approximately RMB 500.5 million. After the completion of the acquisition, the buyer will hold 100% equity of the target company. The announcement stated that the target company is located in the Yangtze River Delta region, with a well-developed pharmaceutical market, and is one of the top six quality pharmaceutical distribution companies in Zhejiang Province. The target company has been deeply cultivating the Zhejiang market for a long time, accumulating rich customer resources. In the past year, its annual sales revenue exceeded RMB 4 billion, with good development prospects. The acquisition is beneficial for Guangzhou Pharmaceuticals to obtain a mature customer network in Zhejiang Province and surrounding areas, further optimize its industrial layout in the East China region, and enhance its coverage and depth in the domestic end market.